Skip to content

New topical drug for DME reports results from a Phase I/II clinical trial

A multi-centre Phase I/II clinical trial has presented initial results for a new topical drug focused on the treatment of diabetic eye disease. The clinical research, reported by Dr. Peter Campochiaro and colleagues at the Wilmer Eye Institute, John Hopkins, showed that mecamylamine drops applied over a course of 1 to 16 weeks were well tolerated and showed no drug related safety problems.